Brief: Casi Pharmaceuticals Announces Precision Autoimmune Therapeutics Has Completed First-Round Financing Of $21 Mln
08/07/2022 12:02
July 8 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS
CO
(PAT) HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION
* CASI HOLDS 15% EQUITY STAKE IN PAT
* CASI PHARMACEUTICALS INC - PAT WILL PAY CASI US $5 MILLION
EQUIVALENT AS FIRST INSTALLMENT OF UPFRONT PAYMENT OF CID-103
SUB-LICENSE AGREEMENT
Source text for Eikon: ID:nPnFZN92a
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary